The SLC1A4 gene is essential in the development and functioning of the central nervous system. Mutations in this gene have been linked to developmental delays and microcephaly, a condition characterized by a smaller head size indicative of abnormal brain development. These conditions can lead to various neurological issues and developmental challenges, significantly affecting an individual's quality of life. Recognizing the importance of early diagnosis and intervention, DNA Labs UAE offers a specialized genetic test aimed at identifying mutations in the SLC1A4 gene.
This test is a crucial tool for families and healthcare providers, offering insights that can lead to better-informed decisions regarding care and management. By understanding the genetic underpinnings of these conditions, tailored therapies and support systems can be implemented, potentially improving developmental outcomes.
The cost of the SLC1A4 related genetic test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect any abnormalities associated with the gene, providing a critical step towards personalized medical care for affected individuals. With the results, healthcare professionals can devise a more targeted approach in managing and supporting the developmental needs of those with mutations in the SLC1A4 gene, emphasizing the test's value in enhancing patient care.
The GNAQ gene is implicated in a variety of biological processes within the human body, including cell signaling pathways that are crucial for normal development and function. Mutations in the GNAQ gene can lead to developmental delays and a range of other medical conditions. Recognizing the importance of early detection and intervention, DNA Labs UAE offers a specialized genetic test specifically designed to identify mutations in the GNAQ gene that may be responsible for developmental delays and related disorders.
This test is a critical tool for healthcare providers and families concerned about genetic conditions affecting development. By analyzing an individual's DNA, the test can pinpoint specific mutations in the GNAQ gene, providing valuable insights into potential health risks and guiding personalized treatment plans.
Priced at 4400 AED, the GNAQ Related Genetic Test at DNA Labs UAE is a comprehensive analysis aimed at those who may be at risk of developmental delays due to genetic factors. The cost of the test reflects the advanced technology and expertise required to accurately identify mutations in the GNAQ gene. Upon completion, the test results can help in making informed decisions about the management and care of affected individuals, ultimately improving their quality of life.
Conducted in a state-of-the-art facility, DNA Labs UAE ensures the confidentiality and accuracy of the testing process, providing support and guidance throughout. This test is a valuable resource for families seeking answers about developmental delays and their potential genetic causes, offering a pathway towards targeted interventions and support.
The KMT2C gene is crucial in human development, playing a significant role in the regulation of gene expression through its involvement in chromatin modification. Mutations in the KMT2C gene can lead to a range of developmental delays and neurodevelopmental disorders, making it a key focus for genetic testing in individuals presenting with such clinical features.
At DNA Labs UAE, a specialized genetic test targeting the KMT2C gene is offered to diagnose conditions related to its mutations. This test is particularly important for families and individuals seeking a deeper understanding of developmental delays and seeking targeted interventions or therapies. The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to identify any mutations in the KMT2C gene that could be responsible for the observed clinical symptoms.
The cost of the KMT2C-related genetic test at DNA Labs UAE is set at 4400 AED. This price reflects the comprehensive nature of the test, encompassing the advanced genetic sequencing technologies used and the expert analysis required to interpret the results accurately. Given the potential impact of a KMT2C gene mutation on an individual's development, this test represents a crucial step towards personalized medical care, offering insights that can guide therapeutic decisions and support.
It's important for individuals considering this test to consult with a genetic counselor or a healthcare professional who can provide detailed information about the implications of the test results and the next steps in the management or treatment of conditions associated with KMT2C gene mutations.
The DNM2 gene DI-CMTB genetic test is a specialized diagnostic tool designed to identify mutations in the Dynamin 2 (DNM2) gene, which are associated with a subtype of Charcot-Marie-Tooth disease known as DI-CMTB. Charcot-Marie-Tooth disease is a group of hereditary disorders that affect the peripheral nerves, leading to muscle weakness and atrophy, particularly in the extremities. The DNM2 gene plays a crucial role in endocytosis and membrane trafficking, and mutations in this gene can disrupt nerve function, contributing to the development of DI-CMTB.
This genetic test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and the sophisticated technology employed to detect mutations with high accuracy. Undergoing this test can be crucial for individuals with a family history of Charcot-Marie-Tooth disease or those exhibiting symptoms, as it can provide a definitive diagnosis of the DI-CMTB subtype. This, in turn, can guide treatment strategies and inform patients about the progression of the disease, potential complications, and the likelihood of passing the condition on to their offspring.
The YARS1 Gene DI-CMTC Genetic Test is a specialized diagnostic assessment conducted to identify mutations in the YARS1 gene, which are associated with Dominant Intermediate Charcot-Marie-Tooth disease (DI-CMTC). Charcot-Marie-Tooth disease is a group of inherited disorders that primarily affect the peripheral nerves, leading to muscle weakness and sensory problems, predominantly in the feet and legs. The YARS1 gene plays a crucial role in the proper functioning of neurons, and mutations in this gene can disrupt nerve function, contributing to the symptoms of DI-CMTC.
This genetic test involves analyzing the patient's DNA to detect any alterations in the YARS1 gene that may indicate the presence of DI-CMTC. It is a vital tool for clinicians in diagnosing the condition, allowing for a more targeted approach to treatment and management of symptoms. Additionally, understanding the genetic basis of the disease can provide important information for family planning and genetic counseling for affected families.
The test is offered at DNA Labs UAE, a leading facility in genetic testing and analysis. The cost of the YARS1 Gene DI-CMTC Genetic Test is 4400 AED. This price reflects the sophisticated technology and expertise required to accurately identify mutations in the YARS1 gene. For patients and families affected by Charcot-Marie-Tooth disease, this test represents a critical step in understanding their condition and navigating the challenges it presents.
The MPZ Gene DI-CMTD Genetic Test is a specialized diagnostic tool designed to identify mutations in the MPZ gene, which are associated with a subtype of Charcot-Marie-Tooth disease known as Dominant Intermediate Charcot-Marie-Tooth Disease Type D (DI-CMTD). Charcot-Marie-Tooth disease is a group of inherited disorders that affect the peripheral nerves, leading to muscle weakness and sensory problems, primarily in the feet and legs, and sometimes the hands and arms.
The MPZ gene plays a crucial role in the functioning and maintenance of the myelin sheath, a protective layer that surrounds nerve fibers. Mutations in this gene can disrupt the normal function of peripheral nerves, leading to the symptoms observed in DI-CMTD. Early and accurate diagnosis through the MPZ Gene DI-CMTD Genetic Test can be critical for the management and treatment of the condition, allowing for targeted therapies and interventions that can improve quality of life.
This genetic test is offered by DNA Labs UAE, a reputable facility known for its advanced diagnostic services. The test is priced at 4400 AED, reflecting the specialized nature of the analysis and the sophisticated technology employed to ensure accurate results. For individuals displaying symptoms of Charcot-Marie-Tooth disease or those with a family history of the condition, the MPZ Gene DI-CMTD Genetic Test can provide essential insights into their genetic makeup, guiding both patients and healthcare providers in making informed decisions about management and treatment strategies.
The GABRG2 Gene Dravet Syndrome Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the GABRG2 gene, which have been linked to Dravet Syndrome, a severe form of epilepsy that begins in infancy. This test is crucial for confirming the diagnosis, guiding treatment options, and providing information for family planning. Dravet Syndrome is characterized by frequent, prolonged seizures often triggered by high temperatures or fever, and it may lead to developmental delays and other neurological issues. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, and analyzing it for specific genetic changes in the GABRG2 gene that are associated with the syndrome.
The test is offered by DNA Labs UAE, a leading facility in genetic testing and diagnostics, ensuring high accuracy and reliability of the results. The cost of the GABRG2 Gene Dravet Syndrome Genetic Test is 4400 AED, reflecting the specialized nature of the test and the sophisticated technology used in the analysis. Opting for this test at DNA Labs UAE not only provides critical insights into the condition but also supports individuals and families in managing the implications of Dravet Syndrome with informed medical and lifestyle decisions.
The SCN2A Gene Dravet Syndrome Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the SCN2A gene, which have been linked to Dravet Syndrome. Dravet Syndrome is a severe form of epilepsy that emerges in the first year of life, characterized by frequent, prolonged seizures often triggered by high temperatures or fever. Beyond seizures, individuals with Dravet Syndrome may also experience developmental delays, speech and walking issues, sleep disturbances, and other health complications.
The SCN2A gene plays a crucial role in the function of brain cells by coding for a protein that is essential for the proper transmission of electrical signals in the nervous system. Mutations in this gene can disrupt these signals, leading to the symptoms observed in Dravet Syndrome. Identifying mutations in the SCN2A gene can confirm a diagnosis of Dravet Syndrome, allowing for tailored treatment plans that can significantly improve the quality of life for affected individuals.
The test offered by DNA Labs UAE involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in their state-of-the-art facilities. The cost of the test is 4400 AED, which reflects the sophisticated technology and expertise required to accurately identify mutations in the SCN2A gene.
By opting for the SCN2A Gene Dravet Syndrome Genetic Test, families and individuals gain access to crucial information that can guide clinical decisions, from medication choices to lifestyle adjustments, ultimately leading to better management of Dravet Syndrome.
The SCN9A Gene Dravet Syndrome Modifier Genetic Test is a specialized diagnostic assessment conducted at DNA Labs UAE, designed to identify mutations in the SCN9A gene, which are known to modify the severity and characteristics of Dravet Syndrome. Dravet Syndrome is a severe form of epilepsy that begins in infancy and is often associated with gene mutations, including those in the SCN1A gene. However, recent research has identified that variations in the SCN9A gene can also influence the disease's course and response to treatment.
This test, priced at 4400 AED, is crucial for individuals diagnosed with Dravet Syndrome or families with a history of the condition, as it provides valuable insights into the genetic underpinnings of the disease. Understanding the specific genetic variations can guide personalized treatment strategies, potentially improving the quality of life for those affected. The testing process at DNA Labs UAE involves a comprehensive analysis of the SCN9A gene, employing state-of-the-art genetic sequencing technologies to ensure accurate and reliable results.
By opting for the SCN9A Gene Dravet Syndrome Modifier Genetic Test, patients and healthcare providers can gain a deeper understanding of the genetic factors contributing to Dravet Syndrome, paving the way for more targeted and effective interventions.
The FRRS1L gene dysautonomia, associated with mutations in the FRRS1L gene, is a rare genetic disorder affecting the autonomic nervous system, which controls involuntary bodily functions such as heart rate, digestion, and respiratory rate. This condition can lead to a wide range of symptoms, including sensory neuropathy, autonomic dysfunction, and, in some cases, intellectual disability or developmental delays.
To diagnose this condition, a specific genetic test targeting the FRRS1L gene can be conducted. This test is crucial for confirming the diagnosis, understanding the condition's progression, and assisting in the management and treatment planning for affected individuals. In the UAE, DNA Labs UAE offers this specialized genetic testing service.
The cost of the FRRS1L-related genetic test at DNA Labs UAE is 4400 AED. The test involves analyzing the patient's DNA sample, usually obtained through a blood draw, to identify mutations in the FRRS1L gene that are indicative of the disorder. Given the complexity and the specialized nature of this genetic test, it represents a critical step towards personalized medicine for patients with symptoms suggestive of FRRS1L gene dysautonomia, offering them a clearer path to appropriate interventions and support.
